ML241 Antagonizes ERK 1/2 Activation and Inhibits Rotavirus Proliferation
Viruses · 2024
DOI: 10.3390/v16040623 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Jinlan Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Develo…. Hauptthemen laut MEDLINE: Rotavirus, Rotavirus Infections, Virus Replication, Antiviral Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Major Science and Technology Special Project of Yunnan Province (Biomedicine), Science and Technology Project of Yunnan Province-general program, CAMS Innovation Fund for Medical Sciences (CIFMS).
Abstract (Originalsprache)
Rotavirus (RV) is the main pathogen that causes severe diarrhea in infants and children under 5 years of age. No specific antiviral therapies or licensed anti-rotavirus drugs are available. It is crucial to develop effective and low-toxicity anti-rotavirus small-molecule drugs that act on novel host targets. In this study, a new anti-rotavirus compound was selected by ELISA, and cell activity was detected from 453 small-molecule compounds. The anti-RV effects and underlying mechanisms of the screened compounds were explored. In vitro experimental results showed that the small-molecule compound ML241 has a good effect on inhibiting rotavirus proliferation and has low cytotoxicity during the virus adsorption, cell entry, and replication stages. In addition to its in vitro effects, ML241 also exerted anti-RV effects in a suckling mouse model. Transcriptome sequencing was performed after adding ML241 to cells infected with RV. The results showed that ML241 inhibited the phosphorylation of ERK1/2 in the MAPK signaling pathway, thereby inhibiting IκBα, activating the NF-κB signaling pathway, and playing an anti-RV role. These results provide an experimental basis for specific anti-RV small-molecule compounds or compound combinations, which is beneficial for the development of anti-RV drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Disease, Kunming 650118, China.
Förderung
- Major Science and Technology Special Project of Yunnan Province (Biomedicine)
- Science and Technology Project of Yunnan Province-general program
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- Yunnan Province Innovative Vaccine Technology and Industrial Transformation Platform
- Science and Technology Project of Yunnan Province—general program
Zitieren
APA
Wang, J., Hu, X., Wu, J., Lin, X., Chen, R., Lu, C., Song, X., Leng, Q., Li, Y., Kuang, X., Li, J., Yao, L., Tang, X., Ye, J., Zhang, G., Sun, M., Zhou, Y., & Li, H. (2024). ML241 Antagonizes ERK 1/2 Activation and Inhibits Rotavirus Proliferation. Viruses. https://doi.org/10.3390/v16040623
Vancouver
Wang J, Hu X, Wu J, Lin X, Chen R, Lu C, et al. ML241 Antagonizes ERK 1/2 Activation and Inhibits Rotavirus Proliferation. Viruses. 2024. doi:10.3390/v16040623
BibTeX
@article{Wang2024,
author = {Wang, Jinlan and Hu, Xiaoqing and Wu, Jinyuan and Lin, Xiaochen and Chen, Rong and Lu, Chenxing and Song, Xiaopeng and Leng, Qingmei and Li, Yan and Kuang, Xiangjing and Li, Jinmei and Yao, Lida and Tang, Xianqiong and Ye, Jun and Zhang, Guangming and Sun, Maosheng and Zhou, Yan and Li, Hongjun},
title = {ML241 Antagonizes ERK 1/2 Activation and Inhibits Rotavirus Proliferation},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16040623}
}
EUVIMED